{"result": {"id": "516cc207-0ac9-477d-9c98-43a783f373c6", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>NEJM<|>ORGANIZATION<|>The New England Journal of Medicine is a prominent medical journal publishing key studies on cholesterol management and cardiovascular disease)\n##\n(\"entity\"<|>LANCET<|>ORGANIZATION<|>The Lancet is a leading medical journal publishing meta-analyses and clinical trials on cholesterol treatments)\n##\n(\"entity\"<|>CIRCULATION<|>ORGANIZATION<|>Circulation is a medical journal publishing research on cardiovascular diseases and treatments)\n##\n(\"entity\"<|>JACC ASIA<|>ORGANIZATION<|>JACC Asia is a medical journal publishing clinical trials on hypercholesterolemia treatments in Asian populations)\n##\n(\"entity\"<|>FRONT PHARMACOL<|>ORGANIZATION<|>Frontiers in Pharmacology is a journal publishing pharmacokinetic studies of new drugs)\n##\n(\"entity\"<|>DIABETES CARE<|>ORGANIZATION<|>Diabetes Care is a medical journal publishing research on diabetes management and complications)\n##\n(\"entity\"<|>LANCET NEUROL<|>ORGANIZATION<|>The Lancet Neurology is a medical journal publishing research on stroke prevention and lipid management)\n##\n(\"entity\"<|>LANCET DIABETES ENDOCRINOL<|>ORGANIZATION<|>The Lancet Diabetes & Endocrinology is a medical journal publishing research on renal function and cholesterol treatments)\n##\n(\"relationship\"<|>ACCORD STUDY GROUP<|>NEJM<|>The Accord Study Group published their findings on combination lipid therapy in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>CANNON C P<|>NEJM<|>Cannon C P published research on ezetimibe added to statin therapy in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>SABATINE M S<|>NEJM<|>Sabatine M S published research on evolocumab in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>FITZGERALD K<|>NEJM<|>Fitzgerald K published research on PCSK9 inhibitors in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS<|>LANCET<|>The Cholesterol Treatment Trialists published meta-analyses in The Lancet<|>8)\n##\n(\"relationship\"<|>WANNER C<|>NEJM<|>Wanner C published research on atorvastatin in patients undergoing hemodialysis in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>FELLSTR?M B C<|>NEJM<|>Fellstr?m B C published research on rosuvastatin in the New England Journal of Medicine<|>8)\n##\n(\"relationship\"<|>O'DONOGHUE M L<|>CIRCULATION<|>O'Donoghue M L published research on evolocumab in Circulation journal<|>8)\n##\n(\"relationship\"<|>QI L T<|>JACC ASIA<|>Qi L T published clinical trial results on tafolecimab in JACC Asia<|>8)\n##\n(\"relationship\"<|>LIAO J W<|>FRONT PHARMACOL<|>Liao J W published pharmacokinetic studies in Frontiers in Pharmacology<|>8)\n##\n(\"relationship\"<|>MYCHALECKYJ J C<|>DIABETES CARE<|>Mychaleckyj J C published research on fenofibrate therapy in Diabetes Care<|>8)\n##\n(\"relationship\"<|>LINZ P E<|>DIABETES CARE<|>Linz P E published research on HDL-C reduction in Diabetes Care<|>8)\n##\n(\"relationship\"<|>AMARENCO P<|>LANCET NEUROL<|>Amarenco P published meta-analyses on stroke prevention in The Lancet Neurology<|>8)\n##\n(\"relationship\"<|>CHOLESTEROL TREATMENT TRIALISTS COLLABORATION<|>LANCET DIABETES ENDOCRINOL<|>Published meta-analysis on renal function and LDL cholesterol lowering in The Lancet Diabetes & Endocrinology<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165923, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 954, "prompt_tokens": 3951, "total_tokens": 4905, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3904}, "prompt_cache_hit_tokens": 3904, "prompt_cache_miss_tokens": 47}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 1016/S0140-6736(05)67667-2.\n［20］Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus［J］. N Engl J Med，2010，362（17）：1563- 1574. DOI：10.1056/NEJMoa1001282.\n［21］CANNON  C  P ， BLAZING  M  A， GI UG LIAN O  R  P ， et al. Ezetimibe added to statin therapy after acute coronary syndromes［J］. N Engl J Med，2015，372（25）：2387-2397. DOI：10.1056/NEJMoa1410489.\n［22］LIAO J W，WANG X，LI Z Y，et al. Pharmacokinetic study of oral 14C-radiolabeled hyzetimibe，A new cholesterol absorption inhibitor［J］ . Front Pharmacol，2021，12：665372. DOI： 10.3389/fphar.2021.665372.\n\n\n\tJuly 2024，Vol.27 No.20     Chinese General Practice \n\n［23］O'DONOGHUE M L，GIUGLIANO R P，WIVIOTT S D，et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease［J］. Circulation，2022，146（15） ： 1109-1119. DOI：10.1161/CIRCULATIONAHA.122.061620.\n［24］QI L T，LIU D X，QU Y L，et al. Tafolecimabin Chinese patients with hypercholesterolemia（CREDIT-4）：a randomized，double- blind，placebo-controlled phase 3 trial［J］ . JACC Asia，2023， 3（4）：636-645. DOI：10.1016/j.jacasi.2023.04.011.\n［25］FITZGERALD K，WHITE S，BORODOVSKY A，et al. A highly durable RNAi therapeutic inhibitor of PCSK9［J］. N EnglJ Med， 2017，376（1）：41-51. DOI：10.1056/NEJMoa1609243.\n［26］SABATINE M S，GIUGLIANO R P，KEECH A C，et al. Evolocumab and clinical outcomes in patients with cardiovascular disease［J］. N Engl J Med，2017，376（18）：1713-1722. DOI：10.1056/NEJMoa1615664.\n［27］Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol- lowering therapy in 18，686 people with diabetes in 14 randomised trials of statins：a meta-analysis［J］. Lancet，2008，371（9607）： 117-125. DOI：10.1016/S0140-6736(08)60104-X.\n［28］Cholesterol Treatment Trialists Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens：a meta-analysis of individual participant data from 28 randomised trials［J］. Lancet Diabetes Endocrinol，2016，4（10）： 829-839. DOI：10.1016/S2213-8587(16)30156-5.\n［29］WANNER C，KRANE V，M?RZ W，et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis［J］. N EnglJ Med，2005，353（3）：238-248.\n［30］FELLSTR?M B C，JARDINE A G，SCHMIEDER R E，et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis［J］ . N Engl J Med，2009，360（14）：1395- 1407. DOI：10.1056/NEJMoa0810177.\n［31］MYCHALECKYJ J  C，CRAVEN T，NAYAK  U，et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants［J］. Diabetes Care，2012，35（5）：1008-1014. DOI：10.2337/dc11-1811.\n［32］LINZ P E，LOVATO L C，BYINGTON R P，et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes：the ACCORD Lipid Trial［J］. Diabetes Care， 2014，37（3）：686-693. DOI：10.2337/dc13-0790.\n［33］AMARENCO P，LABREUCHE J. Lipid management in the prevention of stroke：review and updated meta-analysis of statins for stroke prevention［J］. Lancet Neurol，2009，8（5）：453-463. DOI：10.1016/S1474-4422(09)70058-4.\n［34］AMARENCO P，BOGOUSSLAVSKY J，CALLAHAN A\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ACCORD STUDY GROUP<|>ORGANIZATION<|>The Accord Study Group conducted research on the effects of combination lipid therapy in type 2 diabetes mellitus)\n##\n(\"entity\"<|>CANNON C P<|>PERSON<|>Cannon C P is a researcher involved in studies on ezetimibe added to statin therapy after acute coronary syndromes)\n##\n(\"entity\"<|>GIUGLIANO R P<|>PERSON<|>Giugliano R P is a researcher involved in multiple studies on cholesterol management and cardiovascular disease)\n##\n(\"entity\"<|>LIAO J W<|>PERSON<|>Liao J W is a researcher involved in pharmacokinetic studies of hyzetimibe, a new cholesterol absorption inhibitor)\n##\n(\"entity\"<|>O'DONOGHUE M L<|>PERSON<|>O'Donoghue M L is a researcher involved in studies on long-term evolocumab in patients with established atherosclerotic cardiovascular disease)\n##\n(\"entity\"<|>QI L T<|>PERSON<|>Qi L T is a researcher involved in clinical trials of tafolecimab in Chinese patients with hypercholesterolemia)\n##\n(\"entity\"<|>FITZGERALD K<|>PERSON<|>Fitzgerald K is a researcher involved in developing a highly durable RNAi therapeutic inhibitor of PCSK9)\n##\n(\"entity\"<|>SABATINE M S<|>PERSON<|>Sabatine M S is a researcher involved in studies on evolocumab and clinical outcomes in patients with cardiovascular disease)\n##\n(\"entity\"<|>CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS<|>ORGANIZATION<|>The Cholesterol Treatment Trialists Collaborators conducted meta-analyses on the efficacy of cholesterol-lowering therapy in people with diabetes)\n##\n(\"entity\"<|>WANNER C<|>PERSON<|>Wanner C is a researcher involved in studies on atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis)\n##\n(\"entity\"<|>FELLSTR?M B C<|>PERSON<|>Fellstr?m B C is a researcher involved in studies on rosuvastatin and cardiovascular events in patients undergoing hemodialysis)\n##\n(\"entity\"<|>MYCHALECKYJ J C<|>PERSON<|>Mychaleckyj J C is a researcher involved in studies on the reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants)\n##\n(\"entity\"<|>LINZ P E<|>PERSON<|>Linz P E is a researcher involved in studies on paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes)\n##\n(\"entity\"<|>AMARENCO P<|>PERSON<|>Amarenco P is a researcher involved in meta-analyses of statins for stroke prevention)\n##\n(\"relationship\"<|>CANNON C P<|>GIUGLIANO R P<|>Cannon C P and Giugliano R P collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes<|>7)\n##\n(\"relationship\"<|>SABATINE M S<|>GIUGLIANO R P<|>Sabatine M S and Giugliano R P collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease<|>7)\n##\n(\"relationship\"<|>O'DONOGHUE M L<|>GIUGLIANO R P<|>O'Donoghue M L and Giugliano R P collaborated on research about long-term evolocumab in patients with established atherosclerotic cardiovascular disease<|>7)\n##\n(\"relationship\"<|>CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS<|>ACCORD STUDY GROUP<|>Both organizations conducted research on cholesterol-lowering therapies and their effects on patients with diabetes<|>5)\n##\n(\"relationship\"<|>WANNER C<|>FELLSTR?M B C<|>Wanner C and Fellstr?m B C both conducted research on statin therapy in patients undergoing hemodialysis<|>5)\n##\n(\"relationship\"<|>MYCHALECKYJ J C<|>LINZ P E<|>Mychaleckyj J C and Linz P E both conducted research related to the ACCORD trial and its lipid management outcomes<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_335288c3ccb3289a12b7e1a69a57aadc761faabc8ae869801830933ec0847f40_v2"}